Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: GLP-1 RA Group in at-risk Adults with type 2 diabetes with moderate CV risk - XML Representation

Page standards status: Informative

Raw xml | Download


<Group xmlns="http://hl7.org/fhir">
  <id value="236535"/>
  <meta>
    <versionId value="76"/>
    <lastUpdated value="2025-10-09T20:58:38.128Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-group"/>
  </meta>
  <text>
    <status value="extensions"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Group 236535</b></p><a name="236535"> </a><a name="hc236535"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 76; Last updated: 2025-10-09 20:58:38+0000</p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-exposure-group.html">ExposureGroup</a></p></div><p><b>Artifact Author</b>: Computable Publishing®: MAGIC-to-FEvIR Converter: </p><blockquote><p><b>RelatesTo</b></p><ul><li>type: part-of</li><li>targetReference: MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)</li></ul></blockquote><p><b>CiteAs</b>: </p><div><p>GLP-1 RA Group in at-risk Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Group Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236535. Revised 2025-10-09. Available at: https://fevir.net/resources/Group/236535. Computable resource at: https://fevir.net/resources/Group/236535#json.</p>
</div><p><b>url</b>: <a href="https://fevir.net/resources/Group/236535">https://fevir.net/resources/Group/236535</a></p><p><b>identifier</b>: FEvIR Object Identifier/236535, FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-intervention-group-MAGIC-5288-j1Wqrn-intervention-85390-I-85789</p><p><b>title</b>: GLP-1 RA Group in at-risk Adults with type 2 diabetes with moderate CV risk</p><p><b>status</b>: Active</p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href="mailto:support@computablepublishing.com">support@computablepublishing.com</a></p><p><b>description</b>: </p><div><p>Glucagon-Like Peptide-1 (GLP-1) receptor agonists</p>
</div><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication</a>: Evidence Communication</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ExposureGroup}">ExposureGroup</span></td></tr></table><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>
</div><p><b>type</b>: Person</p><p><b>membership</b>: Enumerated</p><p><b>combinationMethod</b>: All of</p><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Member of</span></p><p><b>value</b>: <a href="Group-236533.html">Adults with type 2 diabetes and established CVD (but no CKD)</a></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>inclusion in Adults with type 2 diabetes with moderate CV risk</p>
</div></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Exposed to</span></p><p><b>value</b>: <a href="Group-236532.html">Glucagon-Like Peptide-1 (GLP-1) receptor agonists</a></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>received GLP-1 RA</p>
</div></blockquote></div>
  </text>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
    <valueContactDetail>
      <name value="Computable Publishing®: MAGIC-to-FEvIR Converter"/>
    </valueContactDetail>
  </extension>
  <extension url="http://hl7.org/fhir/uv/ebm/StructureDefinition/relates-to">
    <extension url="type">
      <valueCode value="part-of"/>
    </extension>
    <extension url="targetReference">
      <valueReference>
        <type value="Composition"/>
        <identifier>
          <type>
            <text value="FEvIR Linking Identifier"/>
          </type>
          <system value="https://fevir.net/FLI"/>
          <value value="MAGIC-5288-j1Wqrn-conversion-report"/>
          <assigner>
            <display value="Computable Publishing LLC"/>
          </assigner>
        </identifier>
        <display
                 value="MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"/>
      </valueReference>
    </extension>
  </extension>
  <extension url="http://hl7.org/fhir/uv/ebm/StructureDefinition/cite-as">
    <valueMarkdown
                   value="GLP-1 RA Group in at-risk Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Group Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236535. Revised 2025-10-09. Available at: https://fevir.net/resources/Group/236535. Computable resource at: https://fevir.net/resources/Group/236535#json."/>
  </extension>
  <url value="https://fevir.net/resources/Group/236535"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="https://fevir.net/FOI"/>
    <value value="236535"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <identifier>
    <type>
      <text value="FEvIR Linking Identifier"/>
    </type>
    <system value="https://fevir.net/FLI"/>
    <value
           value="MAGIC-5288-j1Wqrn-intervention-group-MAGIC-5288-j1Wqrn-intervention-85390-I-85789"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <title
         value="GLP-1 RA Group in at-risk Adults with type 2 diabetes with moderate CV risk"/>
  <status value="active"/>
  <publisher value="Computable Publishing LLC"/>
  <contact>
    <telecom>
      <system value="email"/>
      <value value="support@computablepublishing.com"/>
    </telecom>
  </contact>
  <description value="Glucagon-Like Peptide-1 (GLP-1) receptor agonists"/>
  <useContext>
    <code>
      <system value="https://fevir.net/resources/CodeSystem/179423"/>
      <code value="evidence-communication"/>
      <display value="Evidence Communication"/>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="ExposureGroup"/>
        <display value="ExposureGroup"/>
      </coding>
    </valueCodeableConcept>
  </useContext>
  <copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  <type value="person"/>
  <membership value="enumerated"/>
  <combinationMethod value="all-of"/>
  <characteristic>
    <code>
      <text value="Member of"/>
    </code>
    <valueReference>🔗 
      <reference value="Group/236533"/>
      <type value="Group"/>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="MAGIC-5288-j1Wqrn-population-group-85390-85789"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <display
               value="Adults with type 2 diabetes and established CVD (but no CKD)"/>
    </valueReference>
    <exclude value="false"/>
    <description
                 value="inclusion in Adults with type 2 diabetes with moderate CV risk"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Exposed to"/>
    </code>
    <valueReference>🔗 
      <reference value="Group/236532"/>
      <type value="Group"/>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="MAGIC-5288-j1Wqrn-intervention-85390-I-85789"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <display value="Glucagon-Like Peptide-1 (GLP-1) receptor agonists"/>
    </valueReference>
    <exclude value="false"/>
    <description value="received GLP-1 RA"/>
  </characteristic>
</Group>